Clinical Research Directory

Inclusion Criteria: * 1\. Signed the informed consent form; * 2\. Male or female subjects with 50\~80 years of age; * 3\. Active sub-foveal or juxta-foveal choroidal neovascularization(CNV) lesions secondary to neovascular age-related macular degeneration(nAMD); * 4\. Total lesion area ≤ 12 disc area(DA); * 5\. BCVA letter score measured at screening of 19\~78 letters. Exclusion Criteria: * 1\. History of uveitis in either eye； * 2\. Current active inflammation or infection in the study eye; * 3\. Central foveal scar, fibrosis or atrophy of macular in the study eye; * 4\. Subretinal hemorrhage area in the study eye ≥ 50% of total lesion size; * 5\. Scar or fibrosis area in study eyes ≥ 50% of total lesion size; * 6\. History or any concurrent ocular condition which, in opinion of investigator, could either confound interpretation of efficacy and safety of ASKG712 or require medical or surgical intervention. * 7\. Presence of retinal pigment epithelial tear; * 8\. Previous intraocular operations in the study eye; * 9\. Uncontrolled previous or current glaucoma in either eye, or previous glaucoma filtering operation in the study eye; * 10\. Previous anti-VEGF drug treatment within 60 days prior to screening； * 11\. Diseases that affect intravenous injection and venous blood sampling; * 12\. Systemic autoimmune diseases; * 13\. Any uncontrolled clinical disorders; * 14\. History of allergy or current allergic response to ASKG712 or fluorescein; * 15\. Pregnant or nursing women; * 16\. Subjects should be excluded in the opinion of investigators.